NCT04570488已完成不适用
Predicting Favorable Outcomes in Hospitalized Covid-19 Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,415
- 试验地点
- 1
- 主要终点
- Reduction in days from first low-risk score to discharge
研究概览
简要总结
Testing use of predictive analytics to predict which COVID-19+ patients are at low risk for an adverse event (ICU transfer, intubation, mortality, hospice discharge, re-presentation to the ED, oxygen requirements exceeding nasal cannula at 6L/Min) in the next 96 hours
详细描述
To assess if display of low risk of adverse event in EPIC can safely reduce length of stay and plan for discharge.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult hospitalized COVID19+ patients predicted to have no adverse event at 96 events with a threshold at 90% PPV, with at least one low risk during their admission who are discharged alive and have not been in the ICU
排除标准
- •Age < 18 years not hospitalized for COVID19+.
结局指标
主要结局
Reduction in days from first low-risk score to discharge
时间窗: 96 Hours
Reduction in days from first low-risk score to discharge
次要结局
- Reduction in length of stay (LOS)(96 hours)
- Reduction in GTD vs. LOS(96 hours)
- No change in 30 day re-ED presentation or hospital admission rate for cohort(96 hours)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology EfficacyCovid19NCT04678193Aventyn, Inc.27,000
Unknown
不适用
Predictive Models for Intensive Care Admission and Death of COVID-19COVID19Pneumonia, ViralInflammatory ResponseNCT04401228Clinique Saint Pierre Ottignies60
终止
不适用
COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic DiseasesAxial SpondyloarthritisRheumatoid ArthritisSystemic Lupus ErythematosusPsoriatic ArthritisGiant Cell ArteritisNCT04335747Salome Kristensen53
已完成
不适用
COVID-19 Risk StratificationCoronavirusCoronavirus Sars-Associated as Cause of Disease Classified ElsewhereNCT04339387Brigham and Women's Hospital1,326
终止
2 期
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsCOVID-19Cardiovascular DiseasesCardiovascular Risk FactorNCT04615949Cardiol Therapeutics Inc.90